Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03690154 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
A Phase 1 study, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT03690154 is a Phase 1 study that was terminated before completion, run by Shanghai Fosun Pharmaceutical Industrial Development Co.. The registered enrollment target is 67 participants.
The verdict
NCT03690154, a Phase 1 study, was terminated before completion, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This research study is being done in people with advanced-stage solid tumor cancer. Advanced stage solid tumor cancer is a cancer that forms an abnormal mass of tissue that usually does not contain cysts or liquid areas. Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors include lung cancer, breast cancer, prostate cancer, kidney cancer, colorectal cancer, melanoma and sarcoma. The purpose of this research study is to evaluate the safety of the investigational study drug, FN-1501, at different dose levels. FN-1501 has not previously been given to human subjects. It is intended for the treatment in this study of patients with advanced solid tumor cancers. This study will determine the effects, good and/or bad, on patients' cancer. The main objective of this study is to define the recommended phase 2 dose (RP2D) and maximum tolerated dose (MTD) of FN-1501. The MTD is the highest dose a person can take without having bad side effects, and the RP2D will be the dose of FN-1501 used in future studies.
Interventions
- DRUG FN-1501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03690154
The ClinicalTrials.gov registry entry for NCT03690154 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shanghai Fosun Pharmaceutical Industrial Development Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FN-1501 is the first listed.
NCT03690154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03690154 about?
NCT03690154 is a clinical study titled "A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML". This research study is being done in people with advanced-stage solid tumor cancer. Advanced stage solid tumor cancer is a cancer that forms an abnormal mass of tissue that usually does not contain cysts or liquid areas. Different types of solid tumors are named for the type of cells that form them....
What is the current status of trial NCT03690154?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2018-07-23. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT03690154?
The interventions under investigation include: FN-1501 (DRUG).
Who is sponsoring clinical trial NCT03690154?
This trial is sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.